Acquisition History / Zymeworks / Theravance Biopharma, Inc.
Zymeworks Acquires Theravance Biopharma, Inc.
Announced June 29, 2026 — $929M
What happened
Theravance Biopharma agreed on June 29, 2026 to be acquired by Zymeworks for $17.00 per share in cash plus a contingent value right, representing an equity value of approximately $929M.
- Acquirer
- Zymeworks
- Target
- Theravance Biopharma, Inc.
- Announced
- June 29, 2026
- Price
- $929M
- Industry
- Respiratory and cardiovascular biopharmaceuticals
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did Zymeworks acquire Theravance Biopharma, Inc.?
Zymeworks acquired Theravance Biopharma, Inc. on June 29, 2026. This was Zymeworks's 1st publicly tracked acquisition out of 1 we have on record.
How much did Zymeworks pay for Theravance Biopharma, Inc.?
Zymeworks paid $929M for Theravance Biopharma, Inc..
What does Theravance Biopharma, Inc. do?
Theravance Biopharma agreed on June 29, 2026 to be acquired by Zymeworks for $17.00 per share in cash plus a contingent value right, representing an equity value of approximately $929M.
What other Respiratory and cardiovascular biopharmaceuticals companies has Zymeworks acquired?
Theravance Biopharma, Inc. is Zymeworks's only publicly tracked acquisition in Respiratory and cardiovascular biopharmaceuticals so far.